Company PolyPeptide Group AG

Equities

PPGN

CH1110760852

Pharmaceuticals

Real-time Estimate Cboe Europe 14:15:19 03/05/2024 BST 5-day change 1st Jan Change
29.95 CHF +3.28% Intraday chart for PolyPeptide Group AG +1.01% +71.23%

Business Summary

Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.

Number of employees: 1,273

Sales per Business

CHF in Million2022Weight2023Weight Delta
Custom Projects
48.2 %
141 49.8 % 150 48.2 % +6.75%
Contract Manufacturing
42.3 %
111 39.4 % 132 42.3 % +18.32%
Generics and Cosmetics
9.5 %
30 10.7 % 30 9.5 % -2.08%

Sales per region

CHF in Million2022Weight2023Weight Delta
Europe and Asia
71.0 %
192 67.9 % 221 71.0 % +15.45%
United States
29.0 %
90 32.1 % 90 29.0 % -0.41%

Managers

Managers TitleAgeSince
Chief Executive Officer 52 11/04/23
Chief Tech/Sci/R&D Officer 52 31/12/11
Chief Operating Officer 59 30/11/22
Director/Board Member 71 31/12/05
Investor Relations Contact 59 31/03/21
General Counsel 54 31/12/98
Human Resources Officer 45 08/05/22
Sales & Marketing 52 31/12/03
General Counsel 46 31/08/21

Members of the board

Members of the board TitleAgeSince
Director/Board Member 70 31/12/20
Chairman 67 31/03/21
Director/Board Member 71 31/12/05
Director/Board Member 72 31/12/20
Director/Board Member 59 31/12/20
Director/Board Member 60 31/12/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 33,125,001 12,958,584 ( 39.12 %) 155,494 ( 0.4694 %) 39.12 %

Shareholders

NameEquities%Valuation
18,582,406 56.10 % 625 M CHF
1,100,000 3.321 % 37 M CHF
PRIMECAP Management Co.
3.203 %
1,061,016 3.203 % 36 M CHF
Newtyn Management LLC
3.009 %
996,794 3.009 % 34 M CHF
T. Rowe Price International Ltd.
2.990 %
990,437 2.990 % 33 M CHF
HBM Partners AG (Investment Management)
0.9660 %
320,000 0.9660 % 11 M CHF
Joh. Berenberg, Gossler & Co. KG (Investment Management)
0.3224 %
106,790 0.3224 % 4 M CHF
Aperture Investors UK Ltd.
0.2063 %
68,345 0.2063 % 2 M CHF
Swiss Fund Management AG
0.1811 %
60,000 0.1811 % 2 M CHF
Lupus alpha Asset Management AG
0.1660 %
55,000 0.1660 % 2 M CHF

Company contact information

PolyPeptide Group AG

Neuhofstrasse 24

6340, Baar

+41 435 020 580

http://www.polypeptide.com
address PolyPeptide Group AG(PPGN)

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
29.7 EUR
Average target price
22.24 EUR
Spread / Average Target
-25.14%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. PPGN Stock
  4. Company PolyPeptide Group AG